Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil

Phosphodiesterase type 5 (PDE5) inhibitors are used to treat erectile dysfunction, and growing evidence supports potential cardiovascular utility. Their efficacy declines with reduced nitric-oxide synthase (NOS) activity common to various diseases. We tested whether direct soluble guanylate cyclase (sGC) stimulation restores in vivo cardiovascular modulation by PDE5 inhibition despite acute or chronically suppressed NOS activity. Mice (C57/Bl6; n = 62) were studied by in vivo pressure-volume analysis to assess acute modulation by the PDE5 inhibitor sildenafil (SIL; 100 μg/kg/min) of the cardiac response to isoproterenol (ISO) with or without NOS inhibition [Nω-nitro-l-arginine methyl ester (l-NAME)] and cotreatment by the sGC stimulator 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine (BAY 41-8543). SIL induced mild vasodilation but no basal cardiac effects and markedly blunted ISO-stimulated contractility. Acute BAY 41-8543 at a dose lacking cardiovascular effects did not alter ISO responses. However, after acute l-NAME, SIL ceased to influence cardiovascular function, but adding BAY 41-8543 fully restored SIL effects. After 1 week of l-NAME, neither SIL nor SIL + BAY 41-8543 acutely induced vasodilation or blunted ISO responses. However, sustained BAY 41-8543 despite concurrent NOS inhibition restored the cardiovascular efficacy of SIL. The disparity between acute and chronic NOS inhibition related to diffusion of PDE5 away from myocyte z-bands coupled with reduced protein kinase G activation. Both were restored by sustained sGC costimulation. Thus, PDE5 regulation of adrenergic reserve and systemic vasodilation depends upon NOS-induced cGMP/protein kinase G and can be enhanced by sustained low-level stimulation of sGC. This may prove beneficial for enhancing the efficacy of PDE5 inhibitors in conditions with chronically reduced NOS activity.

[1]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[2]  D. Kass,et al.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation. , 2007, Circulation research.

[3]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007, Circulation.

[4]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[5]  D. Kass,et al.  Phosphodiesterase regulation of nitric oxide signaling. , 2007, Cardiovascular research.

[6]  J. Stasch,et al.  Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure , 2007, Hypertension.

[7]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[8]  D. Kass,et al.  Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. , 2007, Journal of the American College of Cardiology.

[9]  A. Burnett.  The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy , 2006, Journal of clinical hypertension.

[10]  J. Stasch,et al.  Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats , 2006, Hypertension.

[11]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[12]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[13]  M. Cheitlin,et al.  Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. , 2006, Urology.

[14]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[15]  M. Silberbach,et al.  Natriuretic Peptides and Nitric Oxide Stimulate cGMP Synthesis in Different Cellular Compartments , 2006, The Journal of general physiology.

[16]  J. Stasch,et al.  NO‐independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy , 2006, British journal of pharmacology.

[17]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[18]  E. Antunes,et al.  Protective Effects of BAY 41-2272 (sGC Stimulator) on Hypertension, Heart, and Cardiomyocyte Hypertrophy Induced by Chronic L-NAME Treatment in Rats , 2006, Journal of cardiovascular pharmacology.

[19]  W. Seeger,et al.  Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.

[20]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[21]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[22]  F. Priviero,et al.  MECHANISMS UNDERLYING RELAXATION OF RABBIT AORTA BY BAY 41‐2272, A NITRIC OXIDE‐INDEPENDENT SOLUBLE GUANYLATE CYCLASE ACTIVATOR , 2005, Clinical and experimental pharmacology & physiology.

[23]  P. Fisher,et al.  Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. , 2005, Vascular pharmacology.

[24]  R. Zoraghi,et al.  Structural and Functional Features in Human PDE5A1 Regulatory Domain That Provide for Allosteric cGMP Binding, Dimerization, and Regulation* , 2005, Journal of Biological Chemistry.

[25]  Giovanni Donati,et al.  Sildenafil Prevents Endothelial Dysfunction Induced by Ischemia and Reperfusion via Opening of Adenosine Triphosphate–Sensitive Potassium Channels: A Human In Vivo Study , 2005, Circulation.

[26]  D. Kass,et al.  Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[28]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[29]  T. Bivalacqua,et al.  Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats , 2004, International Journal of Impotence Research.

[30]  Saptarsi M. Haldar,et al.  Robust Adenoviral and Adeno-Associated Viral Gene Transfer to the In Vivo Murine Heart: Application to Study of Phospholamban Physiology , 2003, Circulation.

[31]  F. Salloum,et al.  Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse Heart , 2003, Circulation research.

[32]  M. Maclean,et al.  Increased expression of the cGMP‐inhibited cAMP‐specific (PDE3) and cGMP binding cGMP‐specific (PDE5) phosphodiesterases in models of pulmonary hypertension , 2002, British journal of pharmacology.

[33]  T. Yamashita,et al.  Overexpression of endothelial nitric oxide synthase in endothelial cells is protective against ischemia-reperfusion injury in mouse skeletal muscle. , 2002, The American journal of pathology.

[34]  J. Stasch,et al.  Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies , 2002, British journal of pharmacology.

[35]  J. Stasch,et al.  Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies , 2002, British journal of pharmacology.

[36]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[38]  D. Kass,et al.  Minimal force‐frequency modulation of inotropy and relaxation of in situ murine heart , 2001, The Journal of physiology.

[39]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[40]  J. Corbin,et al.  Distinguishing the Roles of the Two Different cGMP-binding Sites for Modulating Phosphorylation of Exogenous Substrate (Heterophosphorylation) and Autophosphorylation of cGMP-dependent Protein Kinase* , 2000, The Journal of Biological Chemistry.

[41]  K. Omori,et al.  A Novel Interaction of cGMP-dependent Protein Kinase I with Troponin T* , 1999, The Journal of Biological Chemistry.

[42]  K. Hirata,et al.  Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. , 1998, The Journal of clinical investigation.

[43]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[44]  S. Kuo,et al.  YC-1, a novel activator of platelet guanylate cyclase. , 1994, Blood.

[45]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.